Performance of seven commercial automated assays for the detection of low levels of anti-Toxoplasma IgG in French immunocompromised patients.

Tiphaine DouetCatherine ArmengolElena CharpentierPamela ChauvinSophie CassaingXavier IriartAntoine BerryJudith Fillaux

Published in: Parasite (Paris, France) (2019)

Commercialized assays for toxoplasmosis screening are not suitable for IgG low-level detection in patients without adapting the supplier thresholds to avoid false negative results and risk generalized toxoplasmosis.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
high throughput
prognostic factors
patient reported outcomes
single cell
patient reported
respiratory failure